Stelara

Evolution step-up growth trajectory upward trajectory
Pharma

How biosimilar developers are embracing next phase of US market

Although the so-called biosimilar ‘void’ could pose challenges to upcoming biosimilar availability, the opportunity it presents is also immense.
John JJson Johnson

J&J charts speedy launch of new psoriasis pill Icotyde

Apr 14, 2026 11:43am
drug prices biologics drug costs IRA money cash payment co-pay

Inside the turning tides of the US biosimilar market

Jan 8, 2026 9:00am
JNJ

J&J logs strong innovative drug sales despite Stelara's decline

Jul 16, 2025 11:19am
JNJ

J&J lifts 2025 sales guidance despite looming tariff threat

Apr 15, 2025 11:55am
The Top Line

A closer look at pharma’s top patent losses in 2025

Mar 21, 2025 9:00am